SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 73747.
  • 2
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 18792.
  • 3
    Treatment of polyarteritis nodosa with cortisone: results after three years. Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel. Br Med J 1960; 1: 1399400.
  • 4
    Frohnert PF, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43: 811.
  • 5
    Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009; 265: 496506.
  • 6
    Slot MC, Tervaert JW, Franssen CF, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 6707.
  • 7
    Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 62131.
  • 8
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 3644.
  • 9
    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum 2005; 52: 24619.
  • 10
    DeGroot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al, on behalf of the European Vasculitis Study Group. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 67080.
  • 11
    Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al, on behalf of the European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 21808.
  • 12
    Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 6718.
  • 13
    Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001; 2: 8597.
  • 14
    Ambler G, Omar RZ, Royston P. A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome. Stat Methods Med Res 2007; 16: 27798.
  • 15
    Royston P. Multiple imputation of missing values: update. Stata J 2005; 5: 188201.
  • 16
    Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 77684.
  • 17
    Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 77989.
  • 18
    Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Necrotizing vasculitis—relapse despite cytotoxic therapy. Adv Exp Med Biol 1993; 336: 47781.
  • 19
    Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody–associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58: 290818.
  • 20
    Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 84252.
  • 21
    Kuross S, Davin T, Kjellstrand CM. Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. Clin Nephrol 1981; 16: 17280.
  • 22
    Pedersen RS, Aunsholt NA. Hemodialysis does not always protect against recurrence of Wegener's granulomatosis. Scand J Urol Nephrol 1990; 24: 2235.
  • 23
    Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 127.
  • 24
    Cohen G, Rudnicki M, Horl WH. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int Suppl 2001; 78: S4852.
  • 25
    Gibbons RA, Martinez OM, Garovoy MR. Altered monocyte function in uremia. Clin Immunol Immunopathol 1990; 56: 6680.
  • 26
    Girndt M. Humoral immune responses in uremia and the role of IL-10. Blood Purif 2002; 20: 4858.
  • 27
    Girndt M, Sester M, Sester U, Kaul H, Kohler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001; 78: S20611.
  • 28
    Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al on behalf of the European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 103643.
  • 29
    Touloumi G, Babiker AG, Kenward MG, Pocock SJ, Darbyshire JH. A comparison of two methods for the estimation of precision with incomplete longitudinal data, jointly modelled with a time-to-event outcome. Stat Med 2003; 22: 316175.
  • 30
    Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 13739.